We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+16.49%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$838M
AUM Growth
+$27.2M
Cap. Flow
-$59.8M
Cap. Flow %
-7.14%
Top 10 Hldgs %
41.9%
Holding
75
New
19
Increased
15
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
A icon
Agilent Technologies
A
+$44.5M
2
BHC icon
Bausch Health
BHC
+$40.6M
3
CSLT
CASTLIGHT HEALTH, INC.
CSLT
+$34.3M
4
RAD
Rite Aid Corporation
RAD
+$23.2M
5
HCA icon
HCA Healthcare
HCA
+$22.6M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$72.5M
2
GILD icon
Gilead Sciences
GILD
+$48.6M
3
ZBH icon
Zimmer Biomet
ZBH
+$34.3M
4
CELG
Celgene Corp
CELG
+$30.9M
5
AZN icon
AstraZeneca
AZN
+$30.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.72%
2 Miscellaneous 7.42%
3 Technology 2.82%
4 Communication Services 1.03%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PPH icon
51
VanEck Pharmaceutical ETF
PPH
$993M
$379K 0.05%
6,500
– –
BBH icon
52
VanEck Biotech ETF
BBH
$460M
$292K 0.03%
+3,208
New +$312K
AGN
53
DELISTED
Allergan Inc
AGN
$222K 0.03%
1,786
-197,941
-99% -$24.1M
AFFX
54
DELISTED
Affymetrix Inc
AFFX
$96K 0.01%
+13,500
New +$109K
VIRX
55
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$66K 0.01%
48
-119
-71% -$138K
AMRN
56
Amarin Corp
AMRN
$295M
– –
-199,410
Closed -$7.86M
AZN icon
57
AstraZeneca
AZN
$252B
– –
-511,120
Closed -$30.3M
GILD icon
58
Gilead Sciences
GILD
$181B
– –
-647,287
Closed -$48.6M
IHF icon
59
iShares US Healthcare Providers ETF
IHF
$1.23B
– –
-15,000
Closed -$280K
ILMN icon
60
Illumina
ILMN
$32.6B
– –
-83,961
Closed -$9.04M
INCY icon
61
Incyte
INCY
$25.2B
– –
-448,998
Closed -$22.7M
MRK icon
62
CALL
Merck
MRK
$366B
– –
-296,060
Closed -$14.1M
MRK icon
63
Merck
MRK
$366B
– –
-2,515
Closed -$120K
PFE icon
64
Pfizer
PFE
$159B
– –
-564,944
Closed -$16.4M
REGN icon
65
Regeneron Pharmaceuticals
REGN
$81.8B
– –
-1,000
Closed -$275K
UHS icon
66
Universal Health Services
UHS
$10.1B
– –
-205,300
Closed -$16.7M
ZBH icon
67
Zimmer Biomet
ZBH
$19.2B
– –
-378,669
Closed -$34.3M
FMI
68
DELISTED
Foundation Medicine, Inc.
FMI
– –
-110,092
Closed -$2.62M
STJ
69
DELISTED
St Jude Medical
STJ
– –
-213,164
Closed -$13.2M
SIRO
70
DELISTED
SIRONA DENTAL SYSTEMS INC COM STK
SIRO
– –
-124,425
Closed -$8.73M
DYAX
71
DELISTED
DYAX CORPORATION
DYAX
– –
-25,000
Closed -$188K
TRNX
72
DELISTED
TORNIER N V SHARES (NLD)
TRNX
– –
-487,577
Closed -$9.16M
FRX
73
DELISTED
FOREST LABORATORIES INC
FRX
– –
-228,100
Closed -$13.7M
CELG
74
DELISTED
Celgene Corp
CELG
– –
-366,036
Closed -$30.9M
WOOF
75
DELISTED
VCA Inc.
WOOF
– –
-306,200
Closed -$9.6M
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2014 Portfolio in Review

As of Q1 2014, Redmile Group held 75 positions worth $838M, up 3.4% from $810M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $59.8M in Q1 2014, closing 20 positions and reducing 20 holdings. Its most notable exit was Gilead Sciences, an estimated $48.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Redmile Group opened a new position in Agilent Technologies worth $43.2M.

  • Redmile Group's largest Q1 2014 buy was Agilent Technologies: 1,080,646 shares worth $43.2M.
  • Redmile Group added most to HCA Healthcare in Q1 2014, an estimated $22.6M increase.
  • Redmile Group's biggest Q1 2014 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $72.5M.
  • Redmile Group fully exited Gilead Sciences in Q1 2014, selling an estimated $48.6M.
  • Redmile Group's ten largest holdings make up 42% of its $838M portfolio in Q1 2014.
  • Redmile Group opened 19 new positions and closed 20 in Q1 2014.
  • Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $838M.

Based on Redmile Group's 13F filing for Q1 2014, filed 15 May 2014.